Hot Features
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody... Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.63 | -7.53582986593 | 21.63 | 21.99 | 19.09 | 520924 | 20.36492069 | CS |
| 4 | -3.07 | -13.307325531 | 23.07 | 23.78 | 18.62 | 575710 | 20.96508632 | CS |
| 12 | 0.59 | 3.03967027306 | 19.41 | 24.25 | 17.63 | 532689 | 21.05169383 | CS |
| 26 | 1.1 | 5.82010582011 | 18.9 | 24.25 | 13.75 | 545345 | 19.04625675 | CS |
| 52 | 8.87 | 79.6945193172 | 11.13 | 24.25 | 8.48 | 555559 | 16.21279922 | CS |
| 156 | -6.25 | -23.8095238095 | 26.25 | 28.09 | 7.8 | 556983 | 15.7615761 | CS |
| 260 | -6.25 | -23.8095238095 | 26.25 | 28.09 | 7.8 | 556983 | 15.7615761 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.